Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.6M
-
Number of holders
-
85
-
Total 13F shares, excl. options
-
41M
-
Shares change
-
-4.6M
-
Total reported value, excl. options
-
$68.5M
-
Value change
-
-$8.51M
-
Put/Call ratio
-
0.21
-
Number of buys
-
47
-
Number of sells
-
-45
-
Price
-
$1.67
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q4 2024
117 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q4 2024.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 85 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41M shares
of 54.6M outstanding shares and own 75.14% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), Redmile Group, LLC (3.69M shares), TANG CAPITAL MANAGEMENT LLC (3.3M shares), MORGAN STANLEY (2.5M shares), BlackRock, Inc. (2.38M shares), MILLENNIUM MANAGEMENT LLC (2.13M shares), VANGUARD GROUP INC (1.89M shares), FMR LLC (1.85M shares), MPM BIOIMPACT LLC (1.39M shares), and Almitas Capital LLC (1.22M shares).
This table shows the top 85 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.